The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

JAK inhibitors

JAK inhibitors

Janus kinase (JAK) proteins promote survival and proliferation of cells by activation of the STAT signaling pathway and are induced by hematopoietic cytokine and growth factor receptor activation. Constitutive activation of JAKs is seen in most patients with MPN and JAK inhibitors, such as ruxolitinib, filgotinib, and tofacitinib, have shown clinical activity in these patients.

| |